Institution
Université de Montréal
Education•Montreal, Quebec, Canada•
About: Université de Montréal is a education organization based out in Montreal, Quebec, Canada. It is known for research contribution in the topics: Population & Poison control. The organization has 45641 authors who have published 100476 publications receiving 4004007 citations. The organization is also known as: University of Montreal & UdeM.
Topics: Population, Poison control, Health care, Receptor, Prostate cancer
Papers published on a yearly basis
Papers
More filters
••
Leiden University Medical Center1, James Cook University Hospital2, Radboud University Nijmegen3, University of Florence4, University Hospital of Basel5, University of Strasbourg6, Leeds Teaching Hospitals NHS Trust7, Centre Hospitalier Universitaire de Grenoble8, University Medical Center Freiburg9, University of Würzburg10, University of Ferrara11, University of Montpellier12, Université de Montréal13, Katholieke Universiteit Leuven14, Freeman Hospital15
TL;DR: Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment, however, HCST conferred a significant long-term event-free survival benefit.
Abstract: Importance High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small phase 2 trials. Objective To compare efficacy and safety of HSCT vs 12 successive monthly intravenous pulses of cyclophosphamide. Design, Setting, and Participants The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a phase 3, multicenter, randomized (1:1), open-label, parallel-group, clinical trial conducted in 10 countries at 29 centers with access to a European Group for Blood and Marrow Transplantation–registered transplant facility. From March 2001 to October 2009, 156 patients with early diffuse cutaneous systemic sclerosis were recruited and followed up until October 31, 2013. Interventions HSCT vs intravenous pulse cyclophosphamide. Main Outcomes and Measures The primary end point was event-free survival, defined as time from randomization until the occurrence of death or persistent major organ failure. Results A total of 156 patients were randomly assigned to receive HSCT (n = 79) or cyclophosphamide (n = 77). During a median follow-up of 5.8 years, 53 events occurred: 22 in the HSCT group (19 deaths and 3 irreversible organ failures) and 31 in the control group (23 deaths and 8 irreversible organ failures). During the first year, there were more events in the HSCT group (13 events [16.5%], including 8 treatment-related deaths) than in the control group (8 events [10.4%], with no treatment-related deaths). At 2 years, 14 events (17.7%) had occurred cumulatively in the HSCT group vs 14 events (18.2%) in the control group; at 4 years, 15 events (19%) had occurred cumulatively in the HSCT group vs 20 events (26%) in the control group. Time-varying hazard ratios (modeled with treatment × time interaction) for event-free survival were 0.35 (95% CI, 0.16-0.74) at 2 years and 0.34 (95% CI, 0.16-0.74) at 4 years. Conclusions and Relevance Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment. However, HCST conferred a significant long-term event-free survival benefit. Trial Registration isrctn.org Identifier:ISRCTN54371254
538 citations
••
TL;DR: In this article, the construct validity of the human resources factor has been examined and a model proposed, and the results show that although there was a link between project success and the personnel factor (based on the correlation analyses), this factor did not have a significant impact on project success.
537 citations
••
Oregon Health & Science University1, Mayo Clinic2, Johns Hopkins University3, Université Paris-Saclay4, University of Texas MD Anderson Cancer Center5, Monash University6, Kaiser Permanente7, Université de Montréal8, Heidelberg University9, Complutense University of Madrid10, University of Copenhagen11, Bristol-Myers Squibb12, VU University Amsterdam13, Radboud University Nijmegen14
TL;DR: Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer and the observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
Abstract: Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases. Patients and Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) to ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses. Ipilimumab 10 mg/kg or placebo maintenance therapy was administered to nonprogressing patients every 3 months. The primary end point was overall survival (OS). Results Four hundred patients were randomly assigned to ipilimumab and 202 to placebo; 399 were treated with ipilimumab and 199 with placebo. Median OS was 28.7 months (95% CI, 24.5 to 32.5 months) in the ipilimumab arm versus 29.7 months (95% CI, 26.1 to 34.2 months) in the placebo arm (hazard ratio, 1.11; 95.87% CI, 0.88 to 1.39; P = .3667). Median progression-free survival was 5.6 months in the ipilimumab arm versus 3.8 with placebo arm (hazard ratio, 0.67; 95.87% CI, 0.55 to 0.81). Exploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab (23%) than with placebo (8%). Diarrhea (15%) was the only grade 3 to 4 treatment-related adverse event (AE) reported in ≥ 10% of ipilimumab-treated patients. Nine (2%) deaths occurred in the ipilimumab arm due to treatment-related AEs; no deaths occurred in the placebo arm. Immune-related grade 3 to 4 AEs occurred in 31% and 2% of patients, respectively. Conclusion Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer. The observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
537 citations
••
Harvard University1, Medical College of Wisconsin2, National Institutes of Health3, Duke University4, University of California, San Francisco5, University of Southern California6, Baylor College of Medicine7, Cincinnati Children's Hospital Medical Center8, University of Pennsylvania9, Memorial Sloan Kettering Cancer Center10, Boston Children's Hospital11, University of Utah12, Northwestern University13, Université de Montréal14, Children's National Medical Center15, University of Texas Southwestern Medical Center16, University of Medicine and Dentistry of New Jersey17, University of British Columbia18, Saint Louis University19, University of Minnesota20, University of California, Los Angeles21, University of Manitoba22, University of Alabama23, University of Michigan24, Stanford University25
TL;DR: Transplants from donors other than matched siblings were associated with excellent survival among infants with SCID identified before the onset of infection.
Abstract: Background The Primary Immune Deficiency Treatment Consortium was formed to analyze the results of hematopoietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primary immunodeficiencies. Factors associated with a good transplantation outcome need to be identified in order to design safer and more effective curative therapy, particularly for children with SCID diagnosed at birth. Methods We collected data retrospectively from 240 infants with SCID who had received transplants at 25 centers during a 10-year period (2000 through 2009). Results Survival at 5 years, freedom from immunoglobulin substitution, and CD3+ T-cell and IgA recovery were more likely among recipients of grafts from matched sibling donors than among recipients of grafts from alternative donors. However, the survival rate was high regardless of donor type among infants who received transplants at 3.5 months of age or younger (94%) and among older infants without prior infection (90%) or with infect...
536 citations
••
TL;DR: The findings reviewed here collectively provide a compelling body of evidence that the function of the sleep spindle is related to intellectual ability and memory consolidation.
536 citations
Authors
Showing all 45957 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yoshua Bengio | 202 | 1033 | 420313 |
Alan C. Evans | 183 | 866 | 134642 |
Richard H. Friend | 169 | 1182 | 140032 |
Anders Björklund | 165 | 769 | 84268 |
Charles N. Serhan | 158 | 728 | 84810 |
Fernando Rivadeneira | 146 | 628 | 86582 |
C. Dallapiccola | 136 | 1717 | 101947 |
Michael J. Meaney | 136 | 604 | 81128 |
Claude Leroy | 135 | 1170 | 88604 |
Georges Azuelos | 134 | 1294 | 90690 |
Phillip Gutierrez | 133 | 1391 | 96205 |
Danny Miller | 133 | 512 | 71238 |
Henry T. Lynch | 133 | 925 | 86270 |
Stanley Nattel | 132 | 778 | 65700 |
Lucie Gauthier | 132 | 679 | 64794 |